FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063042783> ?p ?o ?g. }

• W2063042783 endingPage "1772" @default.
• W2063042783 startingPage "1763" @default.
• W2063042783 abstract "Objective To describe the clinical entity of incipient nonarteritic anterior ischemic optic neuropathy (NAION). Design Cohort study. Participants Fifty-four patients (60 eyes) seen in our clinic from 1973 through 2000. Methods At their first visit to our clinic, all patients gave a detailed ophthalmic and medical history and underwent a comprehensive ophthalmic evaluation, color fundus photography, and fluorescein fundus angiography. At each follow-up visit (of 49 patients [55 eyes]), the same ophthalmic evaluation was performed, except for fluorescein fundus angiography. Main Outcome Measures Clinical features of incipient NAION. Results Mean age (± standard deviation) of the patients was 58.7±15.9 years. Median follow-up time was 6.3 years (interquartile range [IQR], 2.1–8.5). At initial visit, all had optic disc edema (ODE) without any visual loss attributable to NAION. In 55%, the fellow eye had classic NAION; in 25%, incipient progressed to classic NAION (after a median time of 5.8 weeks [IQR, 3.2–10.1]); and in 20%, classic NAION developed after resolution of the first episode of incipient NAION. Patients with incipient, compared with classic, NAION had a greater prevalence of diabetes mellitus (P<0.0001) and lower prevalence of ischemic heart disease (P = 0.046). Patients who progressed to classic NAION versus those who did not were significantly younger (P = 0.025), and their visual acuity worsened in 31% and 0%, respectively, and remained stable in 62% and 98%, respectively; in the eyes with progression, central (in 31%) and peripheral (in 77%) visual fields worsened compared with only 1 eye and 2 eyes, respectively, that did not (P = 0.01 and P<0.0001, respectively); and median time to resolution of ODE in the progressed group was 5.8 weeks (IQR, 4.6–8.7) versus 9.6 weeks (IQR, 6.0–17.7) in those who did not progress. Conclusions The results show that incipient NAION is a distinct clinical entity, with asymptomatic ODE and no visual loss attributable to NAION. When a patient seeks treatment with asymptomatic ODE, incipient NAION must be borne in mind as a strong possibility in those who have had classic NAION in the fellow eye, in diabetics of all ages, and in those with high risk factors for NAION; this can avoid unnecessary and expensive investigations. To describe the clinical entity of incipient nonarteritic anterior ischemic optic neuropathy (NAION). Cohort study. Fifty-four patients (60 eyes) seen in our clinic from 1973 through 2000. At their first visit to our clinic, all patients gave a detailed ophthalmic and medical history and underwent a comprehensive ophthalmic evaluation, color fundus photography, and fluorescein fundus angiography. At each follow-up visit (of 49 patients [55 eyes]), the same ophthalmic evaluation was performed, except for fluorescein fundus angiography. Clinical features of incipient NAION. Mean age (± standard deviation) of the patients was 58.7±15.9 years. Median follow-up time was 6.3 years (interquartile range [IQR], 2.1–8.5). At initial visit, all had optic disc edema (ODE) without any visual loss attributable to NAION. In 55%, the fellow eye had classic NAION; in 25%, incipient progressed to classic NAION (after a median time of 5.8 weeks [IQR, 3.2–10.1]); and in 20%, classic NAION developed after resolution of the first episode of incipient NAION. Patients with incipient, compared with classic, NAION had a greater prevalence of diabetes mellitus (P<0.0001) and lower prevalence of ischemic heart disease (P = 0.046). Patients who progressed to classic NAION versus those who did not were significantly younger (P = 0.025), and their visual acuity worsened in 31% and 0%, respectively, and remained stable in 62% and 98%, respectively; in the eyes with progression, central (in 31%) and peripheral (in 77%) visual fields worsened compared with only 1 eye and 2 eyes, respectively, that did not (P = 0.01 and P<0.0001, respectively); and median time to resolution of ODE in the progressed group was 5.8 weeks (IQR, 4.6–8.7) versus 9.6 weeks (IQR, 6.0–17.7) in those who did not progress. The results show that incipient NAION is a distinct clinical entity, with asymptomatic ODE and no visual loss attributable to NAION. When a patient seeks treatment with asymptomatic ODE, incipient NAION must be borne in mind as a strong possibility in those who have had classic NAION in the fellow eye, in diabetics of all ages, and in those with high risk factors for NAION; this can avoid unnecessary and expensive investigations." @default.
• W2063042783 created "2016-06-24" @default.
• W2063042783 creator A5032245475 @default.
• W2063042783 creator A5037999429 @default.
• W2063042783 date "2007-09-01" @default.
• W2063042783 modified "2023-10-14" @default.
• W2063042783 title "Incipient Nonarteritic Anterior Ischemic Optic Neuropathy" @default.
• W2063042783 cites W1931522398 @default.
• W2063042783 cites W1964528118 @default.
• W2063042783 cites W1974345428 @default.
• W2063042783 cites W1981585322 @default.
• W2063042783 cites W1985042884 @default.
• W2063042783 cites W1985930305 @default.
• W2063042783 cites W1988209247 @default.
• W2063042783 cites W1992132221 @default.
• W2063042783 cites W1997813170 @default.
• W2063042783 cites W2000317075 @default.
• W2063042783 cites W2006597528 @default.
• W2063042783 cites W2017443832 @default.
• W2063042783 cites W2021932351 @default.
• W2063042783 cites W2024594006 @default.
• W2063042783 cites W2026973763 @default.
• W2063042783 cites W202827016 @default.
• W2063042783 cites W2036928561 @default.
• W2063042783 cites W2046157504 @default.
• W2063042783 cites W2057134276 @default.
• W2063042783 cites W2074055223 @default.
• W2063042783 cites W2079272639 @default.
• W2063042783 cites W2086551463 @default.
• W2063042783 cites W2090244381 @default.
• W2063042783 cites W2092640259 @default.
• W2063042783 cites W2117645190 @default.
• W2063042783 cites W2135245101 @default.
• W2063042783 cites W2138226357 @default.
• W2063042783 cites W2152369557 @default.
• W2063042783 cites W4243374353 @default.
• W2063042783 doi "https://doi.org/10.1016/j.ophtha.2006.11.035" @default.
• W2063042783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17391767" @default.
• W2063042783 hasPublicationYear "2007" @default.
• W2063042783 type Work @default.
• W2063042783 sameAs 2063042783 @default.
• W2063042783 citedByCount "86" @default.
• W2063042783 countsByYear W20630427832012 @default.
• W2063042783 countsByYear W20630427832013 @default.
• W2063042783 countsByYear W20630427832014 @default.
• W2063042783 countsByYear W20630427832015 @default.
• W2063042783 countsByYear W20630427832016 @default.
• W2063042783 countsByYear W20630427832017 @default.
• W2063042783 countsByYear W20630427832018 @default.
• W2063042783 countsByYear W20630427832019 @default.
• W2063042783 countsByYear W20630427832020 @default.
• W2063042783 countsByYear W20630427832021 @default.
• W2063042783 countsByYear W20630427832022 @default.
• W2063042783 countsByYear W20630427832023 @default.
• W2063042783 crossrefType "journal-article" @default.
• W2063042783 hasAuthorship W2063042783A5032245475 @default.
• W2063042783 hasAuthorship W2063042783A5037999429 @default.
• W2063042783 hasConcept C118487528 @default.
• W2063042783 hasConcept C119060515 @default.
• W2063042783 hasConcept C141071460 @default.
• W2063042783 hasConcept C2776391266 @default.
• W2063042783 hasConcept C2776474195 @default.
• W2063042783 hasConcept C2776763380 @default.
• W2063042783 hasConcept C2778233873 @default.
• W2063042783 hasConcept C2778257484 @default.
• W2063042783 hasConcept C2779735895 @default.
• W2063042783 hasConcept C2780248432 @default.
• W2063042783 hasConcept C2780498249 @default.
• W2063042783 hasConcept C2780827179 @default.
• W2063042783 hasConcept C2780837183 @default.
• W2063042783 hasConcept C71924100 @default.
• W2063042783 hasConceptScore W2063042783C118487528 @default.
• W2063042783 hasConceptScore W2063042783C119060515 @default.
• W2063042783 hasConceptScore W2063042783C141071460 @default.
• W2063042783 hasConceptScore W2063042783C2776391266 @default.
• W2063042783 hasConceptScore W2063042783C2776474195 @default.
• W2063042783 hasConceptScore W2063042783C2776763380 @default.
• W2063042783 hasConceptScore W2063042783C2778233873 @default.
• W2063042783 hasConceptScore W2063042783C2778257484 @default.
• W2063042783 hasConceptScore W2063042783C2779735895 @default.
• W2063042783 hasConceptScore W2063042783C2780248432 @default.
• W2063042783 hasConceptScore W2063042783C2780498249 @default.
• W2063042783 hasConceptScore W2063042783C2780827179 @default.
• W2063042783 hasConceptScore W2063042783C2780837183 @default.
• W2063042783 hasConceptScore W2063042783C71924100 @default.
• W2063042783 hasIssue "9" @default.
• W2063042783 hasLocation W20630427831 @default.
• W2063042783 hasLocation W20630427832 @default.
• W2063042783 hasOpenAccess W2063042783 @default.
• W2063042783 hasPrimaryLocation W20630427831 @default.
• W2063042783 hasRelatedWork W1989042846 @default.
• W2063042783 hasRelatedWork W2026836276 @default.
• W2063042783 hasRelatedWork W2085330339 @default.
• W2063042783 hasRelatedWork W2113589733 @default.
• W2063042783 hasRelatedWork W2154089267 @default.
• W2063042783 hasRelatedWork W2157615809 @default.
• W2063042783 hasRelatedWork W2196317040 @default.
• W2063042783 hasRelatedWork W3140563418 @default.

• next